Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) EBT Margin (2016 - 2025)

Historic EBT Margin for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 35.4%.

  • Adma Biologics' EBT Margin rose 47300.0% to 35.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 31.88%, marking a year-over-year increase of 127200.0%. This contributed to the annual value of 29.48% for FY2024, which is 404200.0% up from last year.
  • Adma Biologics' EBT Margin amounted to 35.4% in Q3 2025, which was up 47300.0% from 32.87% recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' EBT Margin peaked at 35.4% during Q3 2025, and registered a low of 114.26% during Q1 2021.
  • Its 5-year average for EBT Margin is 16.14%, with a median of 11.93% in 2023.
  • In the last 5 years, Adma Biologics' EBT Margin surged by 1534600bps in 2021 and then plummeted by -5800bps in 2025.
  • Over the past 5 years, Adma Biologics' EBT Margin (Quarter) stood at 30.01% in 2021, then increased by 21bps to 23.59% in 2022, then decreased by -1bps to 23.88% in 2023, then soared by 224bps to 29.53% in 2024, then increased by 20bps to 35.4% in 2025.
  • Its EBT Margin stands at 35.4% for Q3 2025, versus 32.87% for Q2 2025 and 29.14% for Q1 2025.